During the past decade, Dayton NCI Community Oncology Research Program conducted 19 clinical trials. In the 10-year time frame, 19 clinical trials started and 66 clinical trials were completed, i.e. on average, 347.4% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 28 clinical trials were completed. i.e. 933.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Dayton NCI Community Oncology Research Program" #1 sponsor was "National Cancer Institute (NCI)" with 47 trials, followed by "SWOG Cancer Research Network" with 9 trials sponsored, "Alliance for Clinical Trials in Oncology" with 4 trials sponsored, "University of Rochester NCORP Research Base" with 4 trials sponsored and "Gynecologic Oncology Group" with 4 trials sponsored. Other sponsors include 16 different institutions and companies that sponsored additional 21 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Dayton NCI Community Oncology Research Program" #1 collaborator was "National Cancer Institute (NCI)" with 25 trials as a collaborator, "NRG Oncology" with 7 trials as a collaborator, "SWOG Cancer Research Network" with 6 trials as a collaborator, "Cancer and Leukemia Group B" with 5 trials as a collaborator and "NCIC Clinical Trials Group" with 5 trials as a collaborator. Other collaborators include 14 different institutions and companies that were collaborators in the rest 19 trials.

According to Clinical.Site data, the most researched conditions in "Dayton NCI Community Oncology Research Program" are "Recurrent Breast Carcinoma" (6 trials), "Breast Cancer" (5 trials), "Clear Cell Renal Cell Carcinoma" (5 trials), "Recurrent Squamous Cell Lung Carcinoma" (5 trials) and "Stage IIA Breast Cancer AJCC v6 and v7" (5 trials). Many other conditions were trialed in "Dayton NCI Community Oncology Research Program" in a lesser frequency.

Most popular intervention types in "Dayton NCI Community Oncology Research Program" are "Drug" (77 trials), "Other" (63 trials), "Biological" (36 trials), "Procedure" (9 trials) and "Radiation" (7 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (49 trials), "Quality-of-Life Assessment" (24 trials), "Bevacizumab" (14 trials), "Paclitaxel" (14 trials) and "Carboplatin" (12 trials). Other intervention names were less common.

The vast majority of trials in "Dayton NCI Community Oncology Research Program" are 65 trials for "All" genders, 20 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Dayton NCI Community Oncology Research Program". undefined are not yet recruiting, 5 are recruiting, 38 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 36 completed trials in Dayton NCI Community Oncology Research Program, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Dayton NCI Community Oncology Research Program, 4 "Phase 1" clinical trials were conducted, 34 "Phase 2" clinical trials and 52 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".